Caxton Associates LP Allakos Inc. Transaction History

Caxton Associates LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $100,798 - $204,267	33,377 Added 75.18%	77,773 $476,000
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $72,397 - $170,968	27,845 Added 168.24%	44,396 $139,000
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $84,079 - $162,365	16,551 New	16,551 $94,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.